胡潤榜:疫情兩個月間企業家財富損失2.6萬億人幣 馬化騰首次成中國首富
胡潤研究院發布《疫情兩個月後全球企業家財富變化特別報告》,研究胡潤全球富豪榜上的企業家在截至2020年3月31日的兩個月內的財富變化。全球百強企業家近兩月財富損失2.6萬億元人民幣(下同),相當於下跌13%,蒸發了過去兩年半所創造的財富;前十名損失1.4萬億元。
來自視頻會議平台zoom的50歲袁征近兩月財富增長最快,增長了77%,達到565億元。
馬化騰第一次成為中國首富,財富近兩月減少7%,與馬雲同樣2,900億元,馬雲近兩月財富減少9%。恆瑞醫藥(600276.SH)和翰森製藥(03692.HK)的孫飄揚鐘慧娟夫婦超過許家印和李嘉誠,以2,020億元排名第三。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.